The use of stained cytologic direct smears for  ALK  gene rearrangement analysis of lung adenocarcinoma by Betz, Bryan L. et al.
The Use of Stained Cytologic Direct Smears for ALK
Gene Rearrangement Analysis of Lung Adenocarcinoma
Bryan L. Betz, PhD1; Catherine A. Dixon, MLS (ASCP)1; Helmut C. Weigelin, MLS (ASCP)1;
Stewart M. Knoepp, MD, PhD2; and Michael H. Roh, MD, PhD1
BACKGROUND: Rearrangements involving the anaplastic lymphoma kinase (ALK) gene are present in approximately 5%
of lung adenocarcinomas. Crizotinib is approved for the treatment of lung adenocarcinomas harboring ALK rearrange-
ments. Patients with advanced stage lung cancer are not candidates for surgical resection of their primary tumors. For
these patients, cytologic specimens often represent the only diagnostic tissue available. Cell blocks (CBs) are routinely
used for molecular studies; however, insufficient CB cellularity can impede the performance of these assays. METHODS:
Thirty-two cytology cases of lung adenocarcinomas were analyzed by fluorescence in situ hybridization (FISH) for ALK
rearrangements. Diff-Quik–stained smears were examined to identify tumor cell-enriched areas that were marked using a
diamond-tipped scribe. Paired ALK rearrangement FISH was performed using smears and CBs in each case. RESULTS: An
ALK rearrangement was detected on direct smears and CB sections in 5 (16%) and 4 (13%), respectively, of the 32 cases
studied. Concordant FISH results for smears and CBs were observed in 31 (97%) of 32 cases. In the 1 discordant case, an
ALK rearrangement was detected on the direct smear but not in the CB. Reverse transcriptase-polymerase chain reaction
analysis of this CB revealed the presence of an EML4-ALK rearrangement, thereby confirming a false-negative FISH result
in the CB. CONCLUSIONS: Stained cytologic direct smears can be effectively used for ALK rearrangement analysis by
FISH. This approach represents a useful safeguard when insufficient CB cellularity is encountered and could prevent
delays in treatment in this era of precision medicine. Cancer (Cancer Cytopathol) 2013;121:489-99. VC 2013 American
Cancer Society.
KEY WORDS: lung cancer; anaplastic lymphoma kinase (ALK) rearrangement; fluorescence in situ hybridization; cytology;
direct smear; fine-needle aspiration; non-small cell lung cancer; adenocarcinoma; precision medicine.
INTRODUCTION
Lung cancer represents a leading cause of cancer mortality worldwide.1 In the United States, an estimated
226,160 individuals will be diagnosed with lung cancer and approximately 160,340 will die of the disease.2 His-
tologically, lung cancer is dichotomized into 2 general categories: small cell lung carcinoma and non-small cell
lung carcinoma (NSCLC). NSCLCs represent a diverse entity that can be subclassified further into distinct his-
tologic subtypes including adenocarcinoma, squamous cell carcinoma, large cell carcinoma, large cell neuroen-
docrine carcinoma, anaplastic carcinoma, and giant cell carcinoma.3 Of these, adenocarcinoma represents the
most common subtype of lung cancer.4
Lung cancer is associated with a grim overall prognosis because cure is currently achieved in approximately
10% to 15% of patients.5 Approximately 40% of patients are diagnosed with stage IV disease.6 Recently,
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rearrangements involving the anaplastic lymphoma kinase
(ALK) gene were reported in approximately 5% of lung
adenocarcinomas.7,8 Most commonly, these rearrange-
ments are a result of small inversions within the short arm
of chromosome 2 that lead to fusion of portions of the
echinoderm microtubule-associated protein-like 4
(EML4) and ALK genes.5,8 Crizotinib, recently approved
by the US Food and Drug Administration for the treat-
ment of NSCLCs with ALK rearrangements, is a small-
molecule inhibitor of the ALK tyrosine kinase.9 A recent
phase 1 study evaluating 143 patients revealed a response
rate of 60.8% and estimated overall survival rates at 6
months and 12 months of 87.9% and 74.8%,
respectively.10
A large number of patients with lung cancer are diag-
nosed at a late stage of disease and are not candidates for
surgical resection of their primary tumors. For these
patients, small biopsies and cytologic specimens, obtained
through minimally invasive procedures, often represent
the only opportunity to obtain tumor cells and tissue for
diagnosis and necessary molecular studies. Thus, patholo-
gists are assuming increasing responsibilities to optimally
triage cellular material for these purposes. For exfoliative
and aspiration cytology specimens, cell block preparations
are traditionally used for molecular studies. Unfortu-
nately, insufficient cell block cellularity can be encoun-
tered in a significant percentage of cases, resulting in an
obstacle for the performance of these studies.11 This can
result in repeat procedures, for which a satisfactory cell
block is not necessarily guaranteed, and consequent delays
in treatment.
We recently reported that Diff-Quik–stained direct
smears prepared from cytologic samples of lung carci-
noma and melanoma represent a rich source of cellular
material for epidermal growth factor receptor (EGFR) and
KRAS mutational analysis and BRAF mutational analysis,
respectively.12–14 Currently, the prescription of crizotinib
requires the use of the Vysis ALK break apart fluorescence
in situ hybridization (FISH) probe kit (Abbott Molecular,
Des Plaines, IL), which has only been approved for use on
formalin-fixed, paraffin-embedded (FFPE) sections.5
Nonetheless, given the main inherent flaw in relying solely
on cell blocks for molecular studies (the variable cellular-
ity and insufficient cellularity in a significant percentage
of cases11), we sought to investigate the application of
ALK break apart FISH analysis to Diff-Quik–stained
cytologic direct smears. The potential advantages of this
approach over cytologic cell blocks include the ability to
directly assess the smear for specimen adequacy and to
score FISH signals in entire nuclei, rather than truncated
nuclei present in paraffin sections. Hence, to validate this
approach, we tested both stained smears and cell blocks
prepared from cytologic samples of adenocarcinoma, in




The study was approved by the Institutional Review
Board at the University of Michigan. Thirty-two cytology
cases of metastatic pulmonary adenocarcinoma for which
the cell block exhibited sufficient tumor cellularity, as
judged by examination of the initial hematoxylin and eo-
sin (H&E)-stained section, and there existed at least 2
diagnostic Diff-Quik–stained smears were retrieved from
the archive. These included 18 fine-needle aspirate speci-
mens (FNAs), 13 pleural fluids, and 1 pericardial effusion
(Table 1). Cases that were previously identified as being
positive for ALK rearrangement were preferentially
selected, when possible, to increase their representation in
this study. Diff-Quik–stained smears were examined to
identify tumor cell-enriched areas. These areas, onto
which the ALK break apart FISH probe set would be
applied, were marked on the underside of the slides with a
diamond-tipped scribe. The marked smears were then
decoverslipped in xylene at room temperature and subse-
quently destained via the acid-alcohol technique.15 Spe-
cifically, smears were incubated sequentially in 100%
ethanol, 95% ethanol, and 70% ethanol for 2 minutes
each. Subsequently, the smears were placed in acid-alco-
hol (1% hydrochloric acid in 70% ethanol) for 1 hour
and then sequentially washed in running water, Scott tap
water substitute, and twice in water for 15 minutes, 5
minutes, and 1 minute each, respectively. The smears
were then dried and triaged to the Molecular Diagnostics
laboratory for ALK rearrangement FISH.
FISH for ALK Rearrangement
Air-dried destained smears were pretreated with the Vysis
FISH Pretreatment Kit (Abbott Molecular) following
the manufacturer’s instructions. Hybridization of the
Vysis LSI ALK Break Apart Rearrangement Probe (Abbott
Molecular) and slide washing were then performed
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according to the manufacturer’s package insert begin-
ning at the hybridization step. FISH on the cell blocks
was performed on 4-micron paraffin sections following
the standard procedure included with the ALK break
apart probe. Scoring for both smears and cell blocks
was performed according to standard criteria outlined in
the ALK break apart probe package insert. According to
these standard criteria, 50 tumor nuclei are scored for
each case. Orange and green signals that are fused (yel-
low), touching, or separated by a distance< 2 signal
diameters apart are classified as negative for ALK rear-
rangement. Orange and green signals separated by a dis-
tance> 2 signal diameters or a single orange signal
without a corresponding green signal are considered
positive for ALK rearrangement. Cases are considered
positive for ALK rearrangement if> 25 of 50 cells are
positive. An additional 50 cells are scored in cases with
5 to 25 positive cells, and are considered positive for
ALK rearrangement if at least 15 of 100 cells are
positive.
Reverse Transcriptase-Polymerase Chain
Reaction for the EML4-ALK Fusion Transcript
Ten paraffin scrolls of the cell block measuring 10
microns were deparaffinized and digested in cell lysis
buffer (Gentra Puregene; Qiagen, Hilden, Germany) with
125 lg of Proteinase K overnight. RNA was extracted
using TRIzol LS reagent (Life Technologies/Invitrogen,
Carlsbad, Calif). One-step reverse transcriptase-polymer-
ase chain reaction (RT-PCR) was performed using the
GeneAmp Gold RNA PCR Core Kit (Life Technologies/
Applied Biosystems, Foster City, Calif) on an Applied
Biosystems 9700 thermal cycler. Reaction components
for the 50 lL reaction were as follows: 150 ng total of
TABLE 1. FISH Analysis of ALK Gene Rearrangement on Cytologic Smears and Corresponding Cell Blocks
Case Specimen Source
Cytologic Smears Cell Blocks
No. of Cells Scored
ALK Positive/Total
No. of Cells Scored Interpretation
No. of Cells Scored
ALK Positive/Total
No. of Cells Scored Interpretation
1 R paratracheal LN FNA 2/50 (4%) Negative 1/50 (2%) Negative
2 L sixth rib lesion FNA 2/50 (4%) Negative 1/50 (2%) Negative
3 L pleural fluid 0/50 (0%) Negative 2/50 (4%) Negative
4 R pleural fluid 1/50 (2%) Negative 3/50 (6%) Negative
5 L pleural fluid 1/50 (2%) Negative 3/50 (6%) Negative
6 L pleural fluid 2/50 (4%) Negative 2/50 (4%) Negative
7 R pleural fluid 3/50 (6%) Negative 3/50 (6%) Negative
8 R supraclavicular LN FNA 29/50 (58%) Positive 28/100 (28%) Positive
9 R pleural fluid 44/50 (88%) Positive 40/50 (80%) Positive
10 R pleural fluid 1/50 (2%) Negative 1/50 (2%) Negative
11 L neck LN FNA 3/50 (6%) Negative 1/50 (2%) Negative
12 Level 7 LN FNA 2/50 (4%) Negative 3/50 (6%) Negative
13 L hilar mass FNA 3/50 (6%) Negative 3/50 (6%) Negative
14 R pleural fluid 1/50 (2%) Negative 0/50 (0%) Negative
15 Level 4L LN FNA 0/50 (0%) Negative 2/50 (4%) Negative
16 R lower lobe lung FNA 2/50 (4%) Negative 1/50 (2%) Negative
17 L hip mass FNA 4/50 (8%) Negative 0/50 (0%) Negative
18 Level 4R LN FNA 1/50 (2%) Negative 2/50 (4%) Negative
19 Level 10L LN FNA 1/50 (2%) Negative 3/50 (6%) Negative
20 Level 7 LN FNA 26/50 (52%) Positive 3/50 (6%) Negative
21 Mediastinal mass FNA 3/50 (6%) Negative 3/50 (6%) Negative
22 Pericardial fluid 34/50 (68%) Positive 36/50 (72%) Positive
23 Level 7 LN FNA 0/50 (0%) Negative 2/50 (4%) Negative
24 Level 2R LN FNA 4/50 (8%) Negative 2/50 (4%) Negative
25 Level 4R LN FNA 2/50 (4%) Negative 2/50 (4%) Negative
26 L pleural fluid 2/50 (4%) Negative 0/50 (0%) Negative
27 R pleural fluid 1/50 (2%) Negative 3/50 (6%) Negative
28 L pleural fluid 0/50 (0%) Negative 0/50 (0%) Negative
29 R pleural fluid 0/50 (0%) Negative 1/50 (2%) Negative
30 Level 7 LN FNA 0/50 (0%) Negative 1/50 (2%) Negative
31 Level 7 LN FNA 2/50 (4%) Negative 3/50 (6%) Negative
32 R pleural fluid 37/100 (37%) Positive 34/50 (68%) Positive
Abbreviations: ALK, anaplastic lymphoma kinase; FISH, fluorescence in situ hybridization; FNA, fine-needle aspiration; L, left; LN, lymph node; R, right.
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RNA template, 13 RT-PCR buffer, 1.75 mM of magne-
sium chloride, 0.8 mM of dNTP blend (200 lM each),
0.3 lM of EML4 exon 13 forward primer
(50TATGGAGCAAAACTACTGTAGAGC30),9 0.3 lM
of ALK exon 20 reverse primer (50CGGAGCTTGC
TCAGCTTGTA30),16 10 U of RNase inhibitor, 5.0 mM
of dithiothreitol (DTT), 1.25 of lM random hexamers,
and 2.5 U of AmpliTaq Gold DNA. The following ther-
mal cycling conditions were used for the RT-PCR: reverse
transcription at 42C for 12 minutes followed by pre-
PCR denaturation at 95C for 10 minutes and then 40
cycles of denaturation at 94C for 20 seconds, annealing
at 58C for 30 seconds, and primer extension at 72C for
1 minute followed by final extension of amplification
products for 7 minutes. The fusion transcript and break-
point were confirmed by bidirectional Sanger sequencing
of RT-PCR products using the BigDye Terminator 1.1
Cycle Sequencing Kit (Life Technologies/Applied Biosys-
tems) and the above-mentioned PCR primers.
RESULTS
A total of 32 cytology cases of pulmonary adenocarci-
noma for which the paraffin-embedded cell block was
determined to be of sufficient tumor cellularity for satis-
factory ALK FISH evaluation, as judged by examination
of the routinely prepared H&E-stained section, were
retrieved from the archive. These cases are outlined in
Table 1. This approach was used because the Vysis ALK
FISH assay is intended to be used on paraffin sections;
FISH results obtained using this platform would represent
the standard to which the FISH results obtained on cyto-
logic smears would be compared.
FISH for ALK rearrangement was performed on par-
affin sections from each cell block using a commercially
available break apart probe set. FISH was satisfactory for
evaluation in all 32 cases. Four cases were interpreted as
positive for ALK rearrangement (cases 8, 9, 22, and 32 in
Table 1). In 3 cases, 50 tumor cell nuclei were scored and
40, 36, and 34 nuclei, respectively, were scored as positive.
For the fourth case, 100 tumor cell nuclei were scored and
28 of these were scored as positive.
Corresponding Diff-Quik–stained direct smears for
these cases were examined by light microscopy to identify
tumor-enriched areas containing at least 200 tumor cells.
These areas, which ranged in size from 24 mm2 to 132
mm2, were marked by a diamond-tipped scribe. Slides
were decoverslipped and destained, and the marked areas
were analyzed by FISH. All 32 smears were tested success-
fully, 5 of which were positive for ALK rearrangement (2
FNAs and 3 effusion specimens) (Fig. 1). For the 2 FNA
specimens (cases 8 and 20 in Table 1), 50 tumor cell
nuclei were scored; 29 and 26 nuclei, respectively, were
scored as positive. For the 2 effusion specimens (cases 9
and 22 in Table 1), 44 nuclei and 34 nuclei, respectively,
of 50 tumor cell nuclei were scored as positive. For 1 effu-
sion specimen (case 32 in Table 1), 100 tumor cell nuclei
were scored and 37 nuclei scored positive. The remaining
27 cases tested negative for ALK rearrangement (Fig. 2).
In total, 31 of 32 cases (97%) yielded concordant
ALK FISH results in paired cell blocks and smears. The
single discordant case (case 20 in Table 1) tested positive
for ALK rearrangement on the smear but negative on the
corresponding cell block (Fig. 3). The cell block consisted
of dichomatous populations of small lymphocytes and
scattered discrete clusters of tumor cells with enlarged
nuclei (Fig. 3). Only 3 of 50 tumor nuclei in the cell block
section scored positive on FISH, which was insufficient
for an interpretation of a positive ALK rearrangement
result. In contrast, 26 of 50 cells in the corresponding
smear scored positive, thereby meeting the positive result
criteria. To clarify this discrepant result, we next per-
formed RT-PCR to interrogate for the presence or ab-
sence of an EML4-ALK fusion transcript in the cell block
preparation for this case. This analysis was positive for the
EML4-ALK fusion and identified the specific EML4-
ALK transcript as variant 1, which joins exon 13 of EML4
to exon 20 of ALK. Sequencing of the RT-PCR products
confirmed the presence of the EML4-ALK variant 1 rear-
rangement (Fig. 3).
The ages of the 5 patients in whom the ALK FISH
assay was positive for an ALK rearrangement ranged from
31 years to 75 years at the time of diagnosis. Three
patients were male (aged 31 years, 53 years, and 75 years,
respectively) and 2 were female (aged 55 years and 66
years, respectively). Four patients were nonsmokers and 1
reported a 20-year history of smoking cigars. Finally, we
observed that the direct smears, previously analyzed by
FISH, could be restained with the Diff-Quik stain. The
cytomorphologic features of the tumor cells remained
well-preserved in the restained smears (Fig. 4).
DISCUSSION
In this era of precisionmedicine, the discovery of molecular
alterations in NSCLC has revolutionized the management
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of patients with this disease. Patients with NSCLCs harbor-
ing EGFR mutations are candidates for targeted therapy
with geftinib or erlotinib.12,17–20 Approximately 5% of
NSCLCs, especially adenocarcinomas, harbor rearrange-
ments involving ALK; patients with these tumors have been
shown to benefit from targeted therapy with crizotinib.10
With the increased use of targeted therapies in patients
with advanced stage NSCLC, there is an increasing clinical
need to interrogate molecular aberrations in small biopsies
and cytologic specimens of primary and metastatic disease.
Specimen inadequacy remains a problematic issue in a sub-
set of cases in which molecular testing is requested. This
leads to delays in treatment because repeat procedures are
necessary to obtain additional diagnostic material.
To our knowledge to date, only a limited number of
studies have examined the use of direct smears prepared
from cytologic specimens of lung carcinoma for use in
molecular analysis. Our group and others have previously
demonstrated that direct smears of lung adenocarcinoma
represent an effective platform for EGFR and KRASmuta-
tion testing.12,21–24 To our knowledge, there are currently
no reports in the literature that examine ALK rearrange-
ment testing in cytologic smears. Therefore, in the current
study, we extended our investigation by applying FISH
FIGURE 1. Anaplastic lymphoma kinase (ALK) rearrangement-positive lung adenocarcinoma is shown. (A) A representative pho-
tomicrograph obtained from the Diff-Quik–stained direct smear is shown (3 400). (B) ALK rearrangement fluorescence in situ
hybridization performed on the direct smear revealed the presence of the probe signal split in tumor cell nuclei, as indicated by
the arrowheads (3 1000). (C) Representative photomicrograph obtained from the hematoxylin and eosin-stained section pre-
pared from the corresponding cell block is shown (3 400). (D) ALK rearrangement fluorescence in situ hybridization performed
on the cell block section revealed the presence of the probe signal split in tumor cell nuclei, as indicated by the arrowheads (3
1000).
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analysis for ALK rearrangements to direct smears of lung
adenocarcinoma.
Overall, the use of direct smears for molecular test-
ing of NSCLC, via PCR-based or FISH-based assays, is
potentially advantageous over the use of cell blocks for
several reasons. First, air-dried smears can be rapidly
stained using Diff-Quik and directly examined for tumor
cellularity. Especially during on-site assessments of FNA
procedures, Diff-Quik–stained smears can be examined
to determine whether a cytologic sample of sufficient tu-
mor cellularity has been obtained for cytomorphologic
diagnostic evaluation as well as for anticipated molecular
studies while the patient is still accessible. Second, the cell
block cellularity is not definitively known nor guaranteed
at the time of the FNA procedure.11 Third, the use of
smears for FISH-based molecular assays is advantageous
because whole nuclei of tumor cells are analyzed, thereby
avoiding the nuclear truncation and probe signal loss that
is encountered in FISH performed on sections from FFPE
specimens.5
Currently, the Vysis FISH assay for ALK rearrange-
ment has only received FDA approval for use on sections
FIGURE 2. Anaplastic lymphoma kinase (ALK) rearrangement-negative lung adenocarcinoma is shown. (A) A representative pho-
tomicrograph obtained from the Diff-Quik–stained direct smear is shown (3 400). (B) ALK rearrangement fluorescence in situ
hybridization performed on the direct smear revealed the absence of the probe signal split (3 1000). (C) A representative photo-
micrograph obtained from the hematoxylin and eosin-stained section prepared from the corresponding cell block is shown (3
400). (D) ALK rearrangement fluorescence in situ hybridization performed on the cell block section also revealed the absence of
the probe signal split (3 1000).
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FIGURE 3. A discordant case of lung adenocarcinoma is shown in which the anaplastic lymphoma kinase (ALK) rearrangement
was scored as positive on the cytologic smear but not on the cell block. (A) A representative photomicrograph obtained from
the Diff-Quik–stained direct smear is shown (3 400). (B) ALK rearrangement fluorescence in situ hybridization performed on the
direct smear revealed the presence of the probe signal split, as indicated by the arrowheads (3 1000). (C) A representative pho-
tomicrograph obtained from the hematoxylin and eosin-stained section prepared from the corresponding cell block is shown (3
400). (D) ALK rearrangement fluorescence in situ hybridization performed on the cell block section revealed the presence of
subtle probe signal splits (indicated by the arrow) that were of insufficient width to be scored as positive (3 1000). (E) Reverse
transcriptase-polymerase chain reaction was performed using RNA isolated from the cell block to interrogate for the presence or
absence of the echinoderm microtubule-associated protein-like 4 (EML4)-ALK fusion transcript. The polymerase chain reaction
product was purified and analyzed by Sanger sequencing, which confirmed the presence of the EML4-ALK variant 1 rearrange-
ment that joins exon 13 of EML4 to exon 20 of ALK.
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prepared from FFPE blocks.5 In cases for which existing
cytologic preparations represent the only available speci-
men, safeguards are needed to ensure that these can be
used to their fullest potential before subjecting patients to
repeat procedures solely for the purpose of obtaining an
adequate cell or tissue block, an outcome that is not neces-
sarily guaranteed after repeat sampling. In this respect, the
results of the current study demonstrate that cytologic
smears can be effectively used for ALK rearrangement test-
ing. We found the quality of ALK FISH on Diff-Quik–
stained smears to be satisfactory in terms of probe signal
intensity and probe signal-to-noise ratios. Concordance
in ALK FISH results between paired smears and cell
blocks was high (31 of 32 cases); however, a single case
(case 20 in Table 1) tested positive for ALK rearrangement
in the smear but negative on the cell block section. We
noted that the orange and green probe signal splits in the
direct smear of this case were 2 to 3 signal diameters apart,
which only minimally met the 2-signal diameter split cri-
teria for a positive result (Fig. 3). In contrast, the signal
splits observed in the corresponding cell block were
smaller, between 1 to 2 signal diameters apart, and there-
fore did not meet the criteria for positive scoring. The rea-
son for the enhanced signal width separation in the direct
smear of this case compared with the cell block is likely
the result of the larger size of tumor nuclei in the former;
cells on air-dried smears are expected to be larger than cells
exposed to formalin, a fixation agent that causes cellular
shrinkage. Consistent with this, increased nuclear size in
smear preparations compared with corresponding cell
blocks was a general feature we observed throughout this
study (Figs. 1–3). Thus, using direct smears may provide
FIGURE 4. Diff-Quik–stained cytologic smears are shown before and after fluorescence in situ hybridization (FISH) analysis. Pho-
tomicrographs obtained from Diff-Quik–stained direct smears from 2 cases are shown before anaplastic lymphoma kinase (ALK)
rearrangement FISH (A and C, 3 600 and 3 200, respectively). After destaining the smears and subsequent FISH analysis, the
smears were restained with Diff-Quik stain. Photomicrographs of these restained smears are shown (B and D, 3 600 and 3 200,
respectively).
Original Article
496 Cancer Cytopathology September 2013
increased sensitivity for detecting ALK rearrangements
compared with cell blocks. It is interesting to note that
testing smears with their comparatively larger nuclei did
not appear to affect the specificity of the ALK FISH test
because we did not observe false-positive results in these
specimens. The subtle splitting of ALK break apart probe
signals has been previously reported in NSCLCs with
ALK rearrangements and represents a challenge to case
interpretation using the break apart FISH probe strat-
egy.5,7,16,25 The cause of this pattern is related to the
structural nature of ALK rearrangements in NSCLC,
which most frequently involve fusion of EML4 to ALK.
These genes are normally separated by a short distance on
chromosome 2p. Fusion results from a small inversion
that may also include deletion of intervening sequences.8
The effect of this small chromosome 2 inversion is that
the 2 ALK probes become separated by only a short dis-
tance, which can lead to subtle probe splits in cases with
EML4-ALK rearrangements. This contrasts with wide
probe splits that occur in cases with the less common
interchromosomal ALK rearrangements involving the
TFG or KIF5B partner genes.
Detection of the EML4-ALK fusion transcript by
RT-PCR in the cell block for case 20 (Table 1) confirmed
the false-negative ALK FISH result in this cell block. The
specific EML4-ALK fusion transcript identified was vari-
ant 1 (EML4 exon 13 to ALK exon 20), which is the most
common fusion in NSCLC.9 Consistent with these find-
ings, others have reported difficulties in detecting ALK
rearrangements by FISH in cases with variant 1 fusions
because of small FISH signal splits.16 In this respect, the
increased nuclear size, lack of nuclear truncation, and
enhanced cellularity of direct smear preparations com-
pared with FFPE sections may increase the ability to
detect ALK rearrangements by break apart FISH in
NSCLC. Additional studies will be necessary to confirm
this. It is interesting to note that thorough destaining in
acid-alcohol was particularly important to reduce auto-
fluorescence from residual Diff-Quik staining that can
interfere with FISH probe signal visualization. Smears
that contained a large amount of blood sometimes exhib-
ited higher background fluorescence in scattered areas of
the slide, but this did not affect the ability to find an
adequate number of cells to successfully score these cases.
Taking our results and overall experience into con-
sideration, we propose a complementary approach to the
molecular analysis of NSCLCs that provides a safeguard
by eliminating the sole reliance on block preparations for
molecular testing (Fig. 5). Typically, paired direct smears,
one of which is stained using Diff-Quik and the other
stained using the Papanicolaou method, are prepared
from a given FNA pass and the remaining contents are
rinsed in a liquid solution for the preparation of a cell
block. We have previously highlighted another viable
option in which contents expelled from a single needle
pass can be distributed over 3 or more smears.11 This
allows for the preparation of an extra Diff-Quik–stained
FIGURE 5. Workflow for the use of cytologic direct smears
for molecular testing in patients with non-small cell lung can-
cer is shown. A Diff-Quik (DQ)–stained smear can be exam-
ined to identify areas that are enriched with tumor cells. Two
areas can be marked on the underside of the slide with a dia-
mond-tipped scribe. Manual microdissection of tumor cells
can be performed from 1 area for DNA isolation and polymer-
ase chain reaction (PCR)-based molecular diagnostic assays
(eg, epidermal growth factor receptor [EGFR] and/or KRAS
mutation analysis). The slide stained using DQ can then be
destained and the anaplastic lymphoma kinase (ALK) break
apart probe set can be applied to the second area for fluo-
rescence in situ hybridization (FISH) testing. After scoring for
the presence or absence of ALK rearrangements, the smear
can then be restained with DQ and coverslipped, thereby
allowing for inclusion in the diagnostic archive. This slide
does not necessarily need to be sacrificed after molecular
testing.
ALK Rearrangement FISH on Direct Smears/Betz et al
Cancer Cytopathology September 2013 497
smear that can be immediately triaged for molecular test-
ing after it is directly assessed to identify and mark distinct
tumor cell-enriched areas (Fig. 5). Tumor cells can be
manually microdissected from 1 area for DNA isolation
and PCR-based molecular assays such as EGFR mutation
testing.12 After microdissection, the smear can be
destained and the ALK break apart probe set can be hybri-
dized to the second tumor cell-enriched area for FISH
analysis. It is interesting to note that sacrifice of smears
used for molecular testing represents a potential disad-
vantage of this approach.26,27 In the current study, we
demonstrated that the smears can be restained after FISH
analysis. This allows at least for partial preservation of the
slide for inclusion in the diagnostic archive. If the afore-
mentioned strategy of preparing and triaging extra Diff-
Quik–stained smears was not used at the time of an FNA
procedure, a previously coverslipped Diff-Quik–stained
smear could be decoverslipped in xylene and used for mo-
lecular testing.12–14 This overall approach is flexible and
forgiving, and provides an effective safeguard in the mo-
lecular testing of cytologic samples of NSCLCs.
Cytologic direct smears provide a feasible and effec-
tive platform for the molecular diagnostic analysis of
NSCLC. Given the ability to ensure cellular adequacy to
immediately triage smear preparations for molecular
assays, the approach described in the current study repre-
sents a useful alternative to relying on paraffin-embedded
cell blocks for molecular testing. This model has the
potential to facilitate the expeditious management of
patients with NSCLC in this era of precision medicine.
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